… therapies. Herein, we review advances in protein degrader development, the preclinical
research that supported their entry into clinical studies, the available data for protein degraders …

… opportunities to develop degraders that target … protein degradation. We then offer a
comprehensive account of the most promising degraders in development as cancer therapies to …

… Protein degraders for cancer treatment A range of new targeted drugs have been developed
for cancer therapy … of precisely targeted protein degraders as cancer therapeutics, and …

… the desired degradation results. In this paper, we classify PROTACs according to E3 ligase
and summarize the PROTAC degradation strategies for different target proteins (Table 1). …

… To date, PROTACs targeting ~ 50 proteins, many of which are clinically validated … cancer
therapy. This article reviews PROTAC-mediated degradation of critical oncoproteins in cancer, …

… protein by hijacking the cellular protein destruction machinery. Degraders offer several
advantages for cancer therapy including resiliency to acquired mutations in the target protein, …

… of extended target suppression until protein re-synthesis 65 (Fig. 2), … of protein degradation
and contribute to the efficacy of the counterintuitive combination of targeted protein degraders …

… Recently, selective degradation of target proteins by small bifunctional molecules (… Brd4
degraders have been reported and showed more efficient anticancer activities than just protein …

… In conclusion, protein degradation seems a promising approach to expand a synthetic
lethality approach in cancer therapy and to hit specific molecular vulnerabilities in solid tumors. …

Drug discovery in the scope of cancer therapy has been focused on conventional agents …
molecules without affecting their protein levels. An emerging therapeutic strategy that garnered …